Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 2, 2007, Pages 378-382

  Segal, Michael ^a,b   Avital, Avi ^c,d   Berstein, Severina ^e   Derevenski, Andrei ^a   Sandbank, Sergio ^a   Weizman, Abraham ^f,g  

^a Flugelman's Mazra Mental Health Medical Center   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d THE MAX STERN YEZREEL VALLEY COLLEGE   (Israel)

^e Rebecca Sieff Government Hospital   (Israel)

^f GEHA MENTAL HEALTH CENTER   (Israel)

^g TEL AVIV UNIVERSITY   (Israel)

Author keywords

Estradiol; Nonparanoid; Paranoid; Prolactin; Schizophrenia subtypes

Indexed keywords

ESTRADIOL; PROLACTIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DOPAMINERGIC SYSTEM; ENDOCRINE SYSTEM; ESTRADIOL BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RECURRENT DISEASE; SCHIZOAFFECTIVE PSYCHOSIS; STATISTICAL SIGNIFICANCE;

ADULT; ANALYSIS OF VARIANCE; ESTRADIOL; HUMANS; MALE; MIDDLE AGED; PROLACTIN; SCHIZOPHRENIA, PARANOID;

EID: 33846833743     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.09.016     Document Type: Article

References (42)

1. Aleman A., Kahn R.S., and Selten J.P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 60 (2003) 565-571
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed (1994), A.P.A., Washington D.C.
3. AxSYM Estradiol assay, (2001) Abbott Laboratories. Diagnostic Division; 1-8.
4. AxSYM Prolactin assay-a. Microparticle Enzyme Immunoassay (MEIA) for the quantitative measurement of prolactin in human serum and plasma (1997), Abott Laboratories
5. Bergemann N., Mundt C., Parzer P., Jannakos I., Nagl I., Salbach B., et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 73 (2005) 357-366
6. Cyr M., Calon F., Morissette M., and Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 27 (2002) 12-27
7. Davis B.M., Davis K.L., Mohs R.C., Mathe A.A., Rothpearl A.B., Johns C.A., et al. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems. Arch Gen Psychiatry 42 (1985) 259-264
8. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 5 (1994) 27-41
9. Di Paolo T., Poyet P., and Labrie F. Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors. Eur J Pharmacol 17 (1981) 105-106
10. Di Paolo T., Poyet P., and Labrie F. Effect of prolactin and estradiol on rat striatal dopamine receptors. Life Sci 31 (1982) 2921-2929
11. Faraone S.V., Brown W.A., and Laughren T.P. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients. J Clin Psychiatry 48 (1987) 151-154
12. Fink G., Sumner B.E., Rosie R., Grace O., and Quinn J.P. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 16 (1996) 325-344
13. Gordon J.H., Borison R.L., and Diamond B.I. Modulation of dopamine receptor sensitivity by estrogen. Biol Psychiatry 15 (1980) 389-396
14. Green P.S., and Simpkins J.W. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 18 (2000) 347-358
15. Green A.I., Faraone S.V., and Brown W.A. Prolactin shifts after neuroleptic withdrawal. Psychiatry Res 32 (1990) 213-219
16. Hafner H., Behrens S., De Vry J., and Gattaz W.F. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur Arch Psychiatry Clin Neurosci 241 (1991) 65-68
17. Hafner H., Behrens S., De Vry J., and Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res 38 (1991) 125-134
18. Hietala J., Syvalahti E., Vilkman H., Vuorio K., Rakkolainen V., Bergman J., et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naïve schizophrenia. Schizoph Res 35 (1999) 41-50
19. Hochman K.M., and Lewine R.R. Age of menarche and schizophrenia onset in women. Schizophr Res 69 (2004) 183-188
20. Huber T.J., Tettenborn C., Leifke E., and Emrich H.M. Sex hormones in psychotic men. Psychoneuroendocrinology 30 (2005) 111-114
21. Kay S., Fiszbein A., and Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
22. Kendler K.S., McGuire M., Gruenberg A.M., and Walsh D. Outcome and family study of the subtypes of schizophrenia in the west of Ireland. Am J Psychiatry 151 (1994) 849-856
23. Kirkpatrick B., Carpenter W.T., Maeda K., Buchanan R.W., Breier A., and Tamminga C.A. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients. Biol Psychiatry 32 (1992) 1049-1054
24. Ko Y.H., Joe S.H., Cho W., Park J.H., Lee J.J., Jung I.K., et al. Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 53 (2006) 169-175
25. Konnecke R., Hafner H., Maurer K., Loffler W., and Van der Heiden W. Main risk factors for schizophrenia: increased familial loading and pre- and peri-natal complications antagonize the protective effect of estrogen in women. Schizophr Res 44 (2000) 81-93
26. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res 48 (2001) 137-144
27. Kuruvilla A., Peedicayil J., Srikrishna G., Kuruvilla K., and Kanagasabapathy A.S. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 19 (1992) 603-606
28. Lindamer L.A., Lohr J.B., Harris M.J., and Jeste D.V. Gender, estrogen, and schizophrenia. Psychopharmacol Bull 33 (1997) 221-228
29. Magaro P., Abrams L., and Canrell P. The Maine scale of paranoid and nonparanoid schizophrenia: reliability and validity. J Consult Clin Psychol 49 (1981) 438-447
30. Oades R.D., and Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 19 (1994) 373-385
31. Rao M.L., and Kolsch H. Effects of estrogen on brain development and neuroprotection-implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 28 Suppl 2 (2003) 83-96
32. Riecher-Rossler A., Hafner H., Stumbaum M., and Schmidt R. Do estrogens have an antipsychotic action?. Fortschr Neurol Psychiatr 62 (1994) 22-28
33. Rubin R.T. Prolactin and schizophrenia. In: Meltzer H.Y. (Ed). Psychopharmacology: the third generation of progress (1987), Raven Press, New York 803-808
34. Sawada H., Ibi M., Kihara T., Urushitani M., Honda K., Nakanishi M., et al. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J 14 (2000) 1202-1214
35. Schurhoff F., Golmard J.L., Szoke A., Bellivier F., Berthier A., Meary A., et al. Admixture analysis of age at onset in schizophrenia. Schizophr Res 71 (2004) 35-41
36. Seeman M.V. Gender differences in schizophrenia. Can J Psychiatry 27 (1982) 107-112
37. Segal M., Avital A., Rojas M., Hausvater N., Sandbank S., Liba D., et al. Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients - a possible marker for the disease's subtypes. Psychiatry Res 127 (2004) 231-240
38. Spauwen J., Krabbendam L., Lieb R., Wittchen H.U., and van Os J. Sex differences in psychosis: normal or pathological?. Schizophr Res 62 (2003) 45-49
39. Spitzer R.L., Williams J.B., Gibbon M., and First M.B. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 49 (1992) 624-629
40. Taherianfard M., and Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci 58 (2004) 3-9
41. Thaker G.K., Wagman A.M., Kirkpatrick B., and Tamminga C.A. Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism. Biol Psychiatry 25 (1989) 75-86
42. Warner M.D., Walker A.M., D'Souza D.C., Lee D., Nasseri D., and Peabody C.A. Lower prolactin bioactivity in unmedicated schizophrenic patients. Psychiatry Res 102 (2001) 249-254